ERα degrader-2 - ≥99% , CAS No.2235396-63-9

CAS: 2235396-63-9 Cat. No.: E650038 Molecular Weight: 492.53
AVAILABLE TO ORDER
GRADE & PURITY ≥99%
Storage
Store at 2-8°C,Protected from light,Desiccated
Shipped In
Wet ice
 ·  off list, applied to all prices below.
Size
Status
Price
Qty
5mg
E650038-5mg
8-12 wks(?) Production requires sourcing of materials. We appreciate your patience and understanding.
$900.90
10mg
E650038-10mg
8-12 wks(?) Production requires sourcing of materials. We appreciate your patience and understanding.
$1,400.90
25mg
E650038-25mg
8-12 wks(?) Production requires sourcing of materials. We appreciate your patience and understanding.
$2,960.90
Enter a quantity for the sizes you want to add.
🧪

Why this grade

≥99% for sensitive chromatographic and analytical workflows requiring minimal baseline interference.

🌡

Storage & shipping

Store at 2-8°C,Protected from light,Desiccated Ships Wet ice Check lot-specific COA for exact specifications.

📋

Quality documents

SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.

📚

Literature proof

Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.

Overview

ERα degrader-2 is a selective estrogen receptor degrader ( SERD ) with potent binding affinity with ERα ( IC 50 =17.1 nM), good degradation efficacy ( EC 50 =0.3 nM). ERα degrader-2 exhibits favorable pharmacokinetic properties and excellent agentgability, can be used for HER + breast cancer research

In Vitro

ERα degrader-2 (0.01-40 nM) decreases ERα expression and not fully degrades ERα in MCF-7 cells even at a higher biochemical concentration in MCF7 cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

ERα degrader-2 (oral administration; 2-6 mg/kg; QD; 21 days) leads to the significant tumor growth inhibition and decreases tumor volume in mice . ERα degrader-2 (oral gavage; 2 mg/kg; single dose) possesses better pharmacokinetic properties than AZD9496, the plasma exposure (AUC) is 16073.7 h*ng/mL, and the half-life period is 12.1 h, the oral availability is 80.5% . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: MCF-7 human breast cancer xenograft model in nude mice Dosage: 2 mg/kg; 6 mg/kg Administration: Oral administration; 2-6 mg/kg; QD; 21 days Result: Exhibited in vivo efficacy in breast cancer xenograft model.

Form:Solid

IC50& Target:ERα 4.6 nM (IC 50 )

Specifications

Specifications & Purity
≥99%
Biochemical and Physiological Mechanisms
ERα degrader-2 is a selective estrogen receptor degrader ( SERD ) with potent binding affinity with ERα ( IC 50 =17.1 nM), good degradation efficacy ( EC 50 =0.3 nM). ERα degrader-2 exhibits favorable pharmacokinetic properties and excellent agentgability
Storage
Store at 2-8°C, Protected from light, Desiccated
Shipped In
Wet ice
This product requires cold chain shipping. Ground and other economy services are not available.
Action Type
INHIBITOR
Purity
≥99%
Names and Identifiers
Molecular Weight 492.53

Documentation

📋 Safety Data Sheet (SDS)

Comprehensive hazard, handling, storage, and regulatory compliance document.

Download SDS →

✅ Certificate of Analysis (COA)

Lot-specific quality data. Enter your lot number to retrieve the exact COA.

Look up COA →

📊 Datasheet

Quick-reference summary of product specifications and applications.

View datasheet →

🔬 Specification Sheet

Full quality attributes and acceptance criteria for this grade.

View spec sheet →

Advanced Data

Certificates(CoA,COO,BSE/TSE and Analysis Chart)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Solution Calculators
Reviews

Customer Reviews

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.